Dupilumab as an adjuvant treatment for keloid-associated symptoms

Abstract

Diaz et al1 recently reported a case of a 53-year-old African American man with a serendipitous improvement in his keloids after 7 months of treatment with dupilumab for severe atopic dermatitis (AD). In the same study, using real-time polymerase chain reaction, the authors were able to demonstrate the overexpression of helper T cell type 2 (Th2) genes, notably interleukin 4 (IL-4) receptor and interleukin 13 (IL-13), in lesional keloidal tissue. Dupilumab is an IL-4 receptor blocker that effectively inhibits Th2 type cytokines and, therefore, may be a novel treatment option for difficult-to-treat keloids.

Topics & Concepts